JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Sodium phenylbutyrate (4-Phenylbutyric acid sodium; 4-PBA sodium), an orphan drug marketed by Ucyclyd Pharma, is a novel and potent histone deacetylase (HDAC) inhibitor used as an as adjunctive therapy for chronic treatment of urea cycle disorders involving deficiencies of argininosuccinic acid synthetase (AS), ornithine transcarbamylase (OTC), or carbamylphosphate synthetase (CPS). As the metabolites of Sodium phenylbutyrate offer an alternative pathway to the urea cycle to allow excretion of excess nitrogen. It also has potent anti-cancer activity.
References: Neuromolecular Med. 2004; 5(3):235-41; J Neurochem. 2005; 93(5):1087-98; J Biol Chem. 2005; 280(1):556-63.
Chemical Name: sodium 4-phenylbutanoate
InChi Key: VPZRWNZGLKXFOE-UHFFFAOYSA-M
InChi Code: InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9; /h1-3, 5-6H, 4, 7-8H2, (H, 11, 12); /q; +1/p-1
SMILES Code: O=C([O-])CCCC1=CC=CC=C1.[Na+]
4-PBA sodium; Sodium 4-phenylbutyrate; Sodium phenylbutyrate; 4-phenylbutyrate (4-PBA); 4-phenylbutyric acid; Buphenyl
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Recommend by mail
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!